Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 47Pancreatic Neoplasms 43Neoplasm Metastasis 20Carcinoma, Hepatocellular 20Lung Neoplasms 15Ovarian Neoplasms 14Colonic Neoplasms 14Rectal Neoplasms 12Stomach Neoplasms 11Prostatic Neoplasms 11Melanoma 11Cholangiocarcinoma 11Carcinoma, Renal Cell 10Breast Neoplasms 10Sarcoma 8Lymphoma, Non-Hodgkin 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Neuroblastoma 7Hepatoblastoma 7Esophageal Neoplasms 7Barrett Esophagus 7Anus Neoplasms 7Wilms Tumor 6Uterine Cervical Neoplasms 6Medulloblastoma 6Gastrointestinal Neoplasms 6Ependymoma 6Central Nervous System Neoplasms 6Adenocarcinoma Of Esophagus 6

Interventions

veliparib 1ribociclib 1cabozantinib 1X-Rays 1Temozolomide 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Chromogranin A 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × Specimen Handling × Gastrointestinal × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡